Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia

O. Ringdén, M. Labopin, A. Bacigalupo, W. Arcese, U. W. Schaefer, R. Willemze, H. Koc, D. Bunjes, E. Gluckman, V. Rocha, A. Schattenberg, F. Frassoni

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Purpose: Several studies show that allogeneic peripheral blood stem cells (PBSCs) engraft more rapidly than bone marrow (BM). However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS). Patients and Methods: Between January 1994 and December 2000, 3,465 adult patients (older than 15 years of age) were reported to the European Group for Blood and Marrow Transplantation Registry from 224 centers. Among acute myeloid leukemia (AML) patients, 1,537 patients received BM and 757 patients received PBSC. In acute lymphoblastic leukemia (ALL) patients, the corresponding figures were 826 versus 345 patients who were analyzed for engraftment, GVHD, TRM, relapse, LFS, and survival. Results: In multivariate analysis, the recovery of neutrophils and platelets was faster with PBSC than with BM (P <.0001). Chronic GVHD was associated with PBSC in patients with AML (relative risk [RR], 2.11; 95% confidence interval, 1.66 to 2.7; P <.0001) and ALL (RR, 1.56; 95% confidence interval, 1.09 to 2.27; P = .02). PBSC versus BM in patients with AML or ALL was not significantly associated with acute GVHD, TRM, relapse, survival, or LFS. In multivariate analysis of patients with AML, factors significantly associated with improved LFS included first remission at transplant (P <.0001), promyelocytic leukemia (M3) versus other FrenchAmerican-British types (P <.0001), and donor age below median 37 years (P = .02). In patients with ALL, first remission (P <.0001) and methotrexate included in the immunosuppressive regimen (P = .001) were associated with improved LFS. Conclusion: Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM.

Original languageEnglish
Pages (from-to)4655-4664
Number of pages10
JournalJournal of Clinical Oncology
Volume20
Issue number24
DOIs
Publication statusPublished - Dec 15 2002

Fingerprint

Peripheral Blood Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Siblings
Bone Marrow
Graft vs Host Disease
Leukemia
Survival
Transplants
Recurrence
Mortality
Neutrophils
Blood Platelets
Multivariate Analysis
Confidence Intervals
Immunosuppressive Agents
Peripheral Blood Stem Cells
Methotrexate
Registries

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. / Ringdén, O.; Labopin, M.; Bacigalupo, A.; Arcese, W.; Schaefer, U. W.; Willemze, R.; Koc, H.; Bunjes, D.; Gluckman, E.; Rocha, V.; Schattenberg, A.; Frassoni, F.

In: Journal of Clinical Oncology, Vol. 20, No. 24, 15.12.2002, p. 4655-4664.

Research output: Contribution to journalArticle

Ringdén, O, Labopin, M, Bacigalupo, A, Arcese, W, Schaefer, UW, Willemze, R, Koc, H, Bunjes, D, Gluckman, E, Rocha, V, Schattenberg, A & Frassoni, F 2002, 'Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia', Journal of Clinical Oncology, vol. 20, no. 24, pp. 4655-4664. https://doi.org/10.1200/JCO.2002.12.049
Ringdén, O. ; Labopin, M. ; Bacigalupo, A. ; Arcese, W. ; Schaefer, U. W. ; Willemze, R. ; Koc, H. ; Bunjes, D. ; Gluckman, E. ; Rocha, V. ; Schattenberg, A. ; Frassoni, F. / Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 24. pp. 4655-4664.
@article{96be5098558a4891b4900818b2af8e11,
title = "Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia",
abstract = "Purpose: Several studies show that allogeneic peripheral blood stem cells (PBSCs) engraft more rapidly than bone marrow (BM). However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS). Patients and Methods: Between January 1994 and December 2000, 3,465 adult patients (older than 15 years of age) were reported to the European Group for Blood and Marrow Transplantation Registry from 224 centers. Among acute myeloid leukemia (AML) patients, 1,537 patients received BM and 757 patients received PBSC. In acute lymphoblastic leukemia (ALL) patients, the corresponding figures were 826 versus 345 patients who were analyzed for engraftment, GVHD, TRM, relapse, LFS, and survival. Results: In multivariate analysis, the recovery of neutrophils and platelets was faster with PBSC than with BM (P <.0001). Chronic GVHD was associated with PBSC in patients with AML (relative risk [RR], 2.11; 95{\%} confidence interval, 1.66 to 2.7; P <.0001) and ALL (RR, 1.56; 95{\%} confidence interval, 1.09 to 2.27; P = .02). PBSC versus BM in patients with AML or ALL was not significantly associated with acute GVHD, TRM, relapse, survival, or LFS. In multivariate analysis of patients with AML, factors significantly associated with improved LFS included first remission at transplant (P <.0001), promyelocytic leukemia (M3) versus other FrenchAmerican-British types (P <.0001), and donor age below median 37 years (P = .02). In patients with ALL, first remission (P <.0001) and methotrexate included in the immunosuppressive regimen (P = .001) were associated with improved LFS. Conclusion: Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM.",
author = "O. Ringd{\'e}n and M. Labopin and A. Bacigalupo and W. Arcese and Schaefer, {U. W.} and R. Willemze and H. Koc and D. Bunjes and E. Gluckman and V. Rocha and A. Schattenberg and F. Frassoni",
year = "2002",
month = "12",
day = "15",
doi = "10.1200/JCO.2002.12.049",
language = "English",
volume = "20",
pages = "4655--4664",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia

AU - Ringdén, O.

AU - Labopin, M.

AU - Bacigalupo, A.

AU - Arcese, W.

AU - Schaefer, U. W.

AU - Willemze, R.

AU - Koc, H.

AU - Bunjes, D.

AU - Gluckman, E.

AU - Rocha, V.

AU - Schattenberg, A.

AU - Frassoni, F.

PY - 2002/12/15

Y1 - 2002/12/15

N2 - Purpose: Several studies show that allogeneic peripheral blood stem cells (PBSCs) engraft more rapidly than bone marrow (BM). However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS). Patients and Methods: Between January 1994 and December 2000, 3,465 adult patients (older than 15 years of age) were reported to the European Group for Blood and Marrow Transplantation Registry from 224 centers. Among acute myeloid leukemia (AML) patients, 1,537 patients received BM and 757 patients received PBSC. In acute lymphoblastic leukemia (ALL) patients, the corresponding figures were 826 versus 345 patients who were analyzed for engraftment, GVHD, TRM, relapse, LFS, and survival. Results: In multivariate analysis, the recovery of neutrophils and platelets was faster with PBSC than with BM (P <.0001). Chronic GVHD was associated with PBSC in patients with AML (relative risk [RR], 2.11; 95% confidence interval, 1.66 to 2.7; P <.0001) and ALL (RR, 1.56; 95% confidence interval, 1.09 to 2.27; P = .02). PBSC versus BM in patients with AML or ALL was not significantly associated with acute GVHD, TRM, relapse, survival, or LFS. In multivariate analysis of patients with AML, factors significantly associated with improved LFS included first remission at transplant (P <.0001), promyelocytic leukemia (M3) versus other FrenchAmerican-British types (P <.0001), and donor age below median 37 years (P = .02). In patients with ALL, first remission (P <.0001) and methotrexate included in the immunosuppressive regimen (P = .001) were associated with improved LFS. Conclusion: Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM.

AB - Purpose: Several studies show that allogeneic peripheral blood stem cells (PBSCs) engraft more rapidly than bone marrow (BM). However, the data are inconsistent with regard to acute and chronic graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), and leukemia-free survival (LFS). Patients and Methods: Between January 1994 and December 2000, 3,465 adult patients (older than 15 years of age) were reported to the European Group for Blood and Marrow Transplantation Registry from 224 centers. Among acute myeloid leukemia (AML) patients, 1,537 patients received BM and 757 patients received PBSC. In acute lymphoblastic leukemia (ALL) patients, the corresponding figures were 826 versus 345 patients who were analyzed for engraftment, GVHD, TRM, relapse, LFS, and survival. Results: In multivariate analysis, the recovery of neutrophils and platelets was faster with PBSC than with BM (P <.0001). Chronic GVHD was associated with PBSC in patients with AML (relative risk [RR], 2.11; 95% confidence interval, 1.66 to 2.7; P <.0001) and ALL (RR, 1.56; 95% confidence interval, 1.09 to 2.27; P = .02). PBSC versus BM in patients with AML or ALL was not significantly associated with acute GVHD, TRM, relapse, survival, or LFS. In multivariate analysis of patients with AML, factors significantly associated with improved LFS included first remission at transplant (P <.0001), promyelocytic leukemia (M3) versus other FrenchAmerican-British types (P <.0001), and donor age below median 37 years (P = .02). In patients with ALL, first remission (P <.0001) and methotrexate included in the immunosuppressive regimen (P = .001) were associated with improved LFS. Conclusion: Allogeneic PBSC results in faster neutrophil and platelet engraftment and a higher incidence of chronic GVHD than BM. However, acute GVHD, TRM, relapse, survival, and LFS were similar in patients receiving PBSCs versus BM.

UR - http://www.scopus.com/inward/record.url?scp=0037115651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037115651&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.12.049

DO - 10.1200/JCO.2002.12.049

M3 - Article

C2 - 12488410

AN - SCOPUS:0037115651

VL - 20

SP - 4655

EP - 4664

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -